J&J Hit With $2.5M Verdict In 1st Philly Risperdal Trial

By Matt Fair (February 24, 2015, 2:25 PM EST) -- A Philadelphia jury slapped a Johnson & Johnson unit with $2.5 million in damages on Tuesday in the first verdict over the antipsychotic drug Risperdal's connections to abnormal breast growth in males, finding the drugmaker failed to warn an autistic boy's parents and physicians of the risks.

The verdict came after a monthlong trial in the Philadelphia County Court of Common Pleas, in which the jury heard evidence that Janssen Pharmaceuticals Inc. had worked for years to obscure evidence that the drug was linked to growth of female breast tissue — a condition known as gynecomastia — in adolescent boys....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!